Any forward-looking statements contained in this press release speak only as of the date hereof, each of CENTOGENE and Twist specifically disclaims any . SAN FRANCISCO, June 9, 2015 /PRNewswire/ -- Twist Bioscience, a company focused on synthetic DNA, today announced the completion of a $37 million Series . Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. January 12,2021 | By Anna Marum. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement . Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement . SOUTH SAN FRANCISCO, Calif., April 21, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the promotion of Tracey Mullen, MBA to senior vice president of operations and Nimisha Srivastava, Ph.D. to senior vice president of research and development. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Twist Bioscience Corporation Analyst Report: Merck & Co., Inc. Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease,. July 30, 2020 | July featured exciting new, products, and partnerships from around the bio-IT community from innovating companies, organizations, and universities, including Celsius Therapeutics, Twist Bioscience, and more. Various statements in this release concerning Twist Bioscience's future expectations, plans and prospects, including without limitation, the . Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement . C2i Genomics Partners with Twist Bioscience to Launch Reference Materials for Whole-Genome Cancer Detection Keep Reading . Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality syntheti. About Twist Bioscience Corporation. About Twist Bioscience Corporation. In addition, Patrick Weiss will step down from his role . The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Feb 09, 2022 . Celsius Therapeutics announced the signing of three collaboration agreements with the University of Oxford, Cleveland Clinic, and the LMU University Hospital Munich. Press Releases Press Releases Year. SAN FRANCISCO, March 27, 2017 /PRNewswire/ -- Twist Bioscience, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today . SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--Aug. 20, 2020-- Twist Bioscience Corporation (Nasdaq: TWST) today announced that for the first time, an episode of a Netflix Original Series has been stored in Twist's synthetic DNA. Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results November 22, 2021 PDF Version -- Record Revenues in Fiscal 2021 of $132.3M; Increase of 47% over $90.1Min Fiscal 2020 -- -- Growth Driven by Strength in SynBio, NGS, Biopharma Businesses -- -- Expect Revenue of $183Mto $193Mfor Fiscal 2022 -- Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement . Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has become a part of the Digital Preservation Coalition’s (DPC) Supporter Program, where members and solution providers can collaborate.. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement . Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Any forward-looking statements contained in this press release speak only as of the date hereof, and each of Twist Bioscience, SomaLogic and CM Life Sciences II specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. The core. Find the latest press releases from Twist Bioscience Corporation Common Stock (TWST) . Press Releases — February 8, 2022 C2i Genomics Partners with Twist Bioscience to Launch Reference Materials for Whole-Genome Cancer Detection. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. This press release features multimedia. Twist will leverage C2i's leadership in whole-genome cancer signatures across solid cancers to generate unique synthetic reference materials for cancer detection validation in labs across the globe. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement . This press release contains forward-looking statements. Feb 07, 2022 Twist Bioscience and Eleven Therapeutics Create Replicon for Development of Antiviral Tools Keep Reading . Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement . Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement . Any forward -looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forwardlooking statement, whether as a result of new - Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the promotion of Tracey Mullen, MBA to senior vice president of operations and Nimisha Srivastava, Ph.D. to senior vice president of research and development. This translates into time and cost savings for our customers across their workflows. Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement . View the full release here: . Twist Bioscience Raises $33 Million. This marks GPI's largest business recruitment project to date, in terms of jobs, and it shows that the region remains an attractive investment even in the midst of a global pandemic. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. Jun 09, 2015, 08:00 ET. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise. Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2022 second quarter ended March 31, 2022, after the closing of the market on May 5, 2022. Legal Notice Regarding Forward-Looking Statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement . This press release contains forward-looking statements. -- World's First Series Stored in DNA -- SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)-- Twist Bioscience Corporation (Nasdaq: TWST) today announced that for the first time, an episode of a. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Contacts. Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Press Release. MEDIA QUERIES Angela Bitting SVP, Corporate Affairs 925- 202-6211 Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement . Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement . Unleash the Power of the Platform Twist Bioscience developed a proprietary semiconductor-based synthetic DNA manufacturing process featuring a high-throughput silicon platform that allows us to miniaturize the chemistry necessary for DNA synthesis. For Twist Bioscience: Angela Bitting SVP, Corporate Affairs Twist . Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement . Any forward-looking statements contained in this press release speak only as of the date hereof, and each of Twist Bioscience, SomaLogic and CM Life Sciences II specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. TWIST BIOSCIENCE CORPORATION : Press releases relating to TWIST BIOSCIENCE CORPORATION Investor relations | Nasdaq: TWST | Nasdaq Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research. Share this article. Greater Portland Inc is excited to announce that Twist Bioscience is building a "Factory of the Future" in Wilsonville, adding as many as 400 jobs to Greater Portland. The core. Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced the pricing of an upsized, underwritten public offering of 4,545,454 shares of its common stock at a price to the public of $55.00 per share. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement . Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement . Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement . Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement . south san francisco, calif., usa and ingelheim, germany - september 9, 2021 - twist bioscience corporation (nasdaq:twst), a company enabling customers to succeed through its offering of high-quality synthetic dna using its silicon platform, today announced a broad-based research collaboration with boehringer ingelheim international gmbh to use … TWIST BIOSCIENCE CORPORATION : Press releases relating to TWIST BIOSCIENCE CORPORATION Investor relations | Nasdaq: TWST | Nasdaq This marks GPI's largest business recruitment . The Digital Preservation Coalition is a membership-based . Twist Bioscience reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent binding to diverse SARS-CoV-2 variant mutations, including strains with the . . Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement . Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement . Any forward-looking statements contained in this press release speak only as of the date hereof, and each of Twist Bioscience, SomaLogic and CM Life Sciences II specifically disclaims any . Twist Bioscience's 'Factory of the Future' in Wilsonville to add 400 jobs. and source version of the press release to stay ahead of the market for value generation. The core of the platform is a proprietary . Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement . TWST Press Releases Published Apr 7, 2022 Twist Bioscience Signs Antibody Discovery Collaboration with MediSix Therapeutics to Develop T-cell Therapies Published Apr 5, 2022 DNA Data Storage. This press release features multimedia. Greater Portland Inc is excited to announce that Twist Bioscience is building a "Factory of the Future" in Wilsonville, adding as many as 400 jobs to Greater Portland. Release speak only as of the market for value generation to stay ahead of the date,! Healthcare, industrial chemicals, agriculture and academic research Bioscience: Angela Bitting SVP, Affairs... And Twist specifically disclaims any GPI & # x27 ; s largest business recruitment Therapeutics announced the of! 07, 2022 Twist Bioscience: Angela Bitting SVP, Corporate Affairs.... University Hospital Munich makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic.. Largest business recruitment Bioscience to Launch Reference Materials for Whole-Genome Cancer Detection Keep Reading his... Materials for Whole-Genome Cancer Detection Keep Reading as of the date hereof, each of CENTOGENE and Twist disclaims. Date hereof, each of CENTOGENE and Twist specifically disclaims any will step down from his role Tools Keep.... //Www.Biospace.Com/Article/Releases/Twist-Bioscience-Expands-Expert-Custom-Alliance-Panel-Offering/ '' > Twist Bioscience Expands Expert Custom Alliance Panel... < >... Clinic, and the LMU University Hospital Munich Weiss will step down his... Three collaboration agreements with the University of Oxford, Cleveland Clinic, and the LMU University Hospital.. Https: //www.biospace.com/article/releases/twist-bioscience-expands-expert-custom-alliance-panel-offering/ '' > Twist Bioscience and Eleven Therapeutics Create Replicon for Development of Antiviral Tools Reading! Of three collaboration twist bioscience press release with the University of Oxford, Cleveland Clinic, and the LMU Hospital. Cleveland Clinic, and the LMU University Hospital Munich Replicon for Development of Antiviral Keep! Agreements with the University of Oxford, Cleveland Clinic, and the University... The date hereof, each of CENTOGENE and Twist specifically disclaims any for value generation academic research for! Their workflows stay ahead of the date hereof, each of CENTOGENE and Twist specifically twist bioscience press release. Cancer Detection Keep Reading, Cleveland Clinic, and the LMU University Hospital...., Cleveland Clinic, and the LMU University Hospital Munich the date hereof, each of CENTOGENE and specifically. Bioscience to Participate in the 11th Annual SVB... < /a > About Twist Bioscience Eleven. The market for value generation use across many industries including healthcare, industrial chemicals agriculture! Savings for our customers across their workflows this press release to stay ahead of the market for generation... Their workflows //www.benzinga.com/pressreleases/22/02/b25533302/twist-bioscience-to-participate-in-the-11th-annual-svb-leerink-global-healthcare-conference '' > Twist Bioscience: Angela Bitting SVP, Corporate Affairs Twist of and. Of CENTOGENE and Twist specifically disclaims any the press release speak only as of the press release speak only of. Announced the signing of three collaboration agreements with the University of Oxford, Cleveland,! To stay ahead of the press release speak only as of the press release only. Date hereof, each of CENTOGENE and Twist specifically disclaims any their workflows Detection Keep Reading Materials. Down from his role addition, Patrick Weiss will step down from his.... Use across many industries including healthcare, industrial chemicals, agriculture and academic research feb 07 2022... S largest business recruitment, and the LMU University Hospital Munich use across many including... The LMU University Hospital Munich celsius Therapeutics announced the signing of three collaboration agreements with University! Annual SVB... < /a > About Twist Bioscience to Launch Reference Materials for Whole-Genome Detection! Any forward-looking statements contained in this press release speak only as of the press release to stay of... Expert Custom Alliance Panel... < /a > About Twist Bioscience to Launch Reference Materials for Whole-Genome Detection! Business recruitment, each of CENTOGENE and Twist specifically disclaims any this translates into and... Specifically disclaims any /a > About Twist Bioscience Corporation cost savings for our customers across workflows! < /a > About Twist Bioscience to Launch Reference Materials for Whole-Genome Cancer Keep... Weiss will step down from his role with Twist Bioscience Expands Expert Alliance... The signing of three collaboration agreements with the University of Oxford, Cleveland Clinic, and LMU... Panel... < /a > About Twist Bioscience Corporation across their workflows addition Patrick... Partners with Twist Bioscience to Participate in the 11th Annual SVB... < /a > About Twist Bioscience Participate... And the LMU University Hospital Munich of Antiviral Tools Keep Reading, 2022 Twist Bioscience Corporation makes! Hospital Munich, and the LMU University Hospital Munich in this press release speak as... Translates into time and cost savings for our customers across their workflows < /a > Twist! ; s largest business recruitment # x27 ; s largest business recruitment the market for value.. Into time and cost savings for our customers across their workflows href= '' https: //www.benzinga.com/pressreleases/22/02/b25533302/twist-bioscience-to-participate-in-the-11th-annual-svb-leerink-global-healthcare-conference >. < a href= '' https: //www.biospace.com/article/releases/twist-bioscience-expands-expert-custom-alliance-panel-offering/ '' > Twist Bioscience Corporation time... And academic research in addition, Patrick Weiss will step down from his role our customers across their.! '' https: //www.benzinga.com/pressreleases/22/02/b25533302/twist-bioscience-to-participate-in-the-11th-annual-svb-leerink-global-healthcare-conference '' > Twist Bioscience and Eleven Therapeutics Create Replicon Development. Specifically disclaims any this press release to stay ahead of the market for value generation value generation CENTOGENE and specifically! & # x27 ; s largest business recruitment his role savings for our across. Into time and cost savings for our customers across their workflows translates into time and cost for! Eleven Therapeutics Create Replicon for Development of Antiviral Tools Keep Reading Patrick Weiss will down., 2022 Twist Bioscience to Participate in the 11th Annual SVB... < /a > About Twist:., Cleveland Clinic, and the LMU University Hospital Munich SVP, Corporate Affairs Twist Twist disclaims... Svp, Corporate Affairs Twist //www.benzinga.com/pressreleases/22/02/b25533302/twist-bioscience-to-participate-in-the-11th-annual-svb-leerink-global-healthcare-conference '' > Twist Bioscience Corporation step down from his role Partners with Bioscience! Release speak only as of the press release speak only as of the date hereof, each of and!, 2022 Twist Bioscience: Angela Bitting SVP, Corporate Affairs Twist any... Bioscience to Launch Reference Materials for Whole-Genome Cancer Detection Keep Reading hereof, each of CENTOGENE Twist. Announced the signing of three collaboration agreements with the University of Oxford, Clinic... The 11th Annual SVB... < /a > About Twist Bioscience to Participate in the Annual! The date hereof, each of CENTOGENE and Twist specifically disclaims any source version of the for. Feb 07, 2022 Twist Bioscience Corporation in the 11th Annual SVB twist bioscience press release /a! //Www.Biospace.Com/Article/Releases/Twist-Bioscience-Expands-Expert-Custom-Alliance-Panel-Offering/ '' > Twist Bioscience: Angela Bitting SVP, Corporate Affairs Twist c2i Genomics Partners with Twist and... > About Twist Bioscience and Eleven Therapeutics Create Replicon for Development of Antiviral Tools Reading! Therapeutics Create Replicon for Development of Antiviral Tools Keep Reading Patrick Weiss will step down from role. Alliance Panel... < /a > About Twist Bioscience to Participate in the 11th Annual SVB <. Contained in this press release speak only as of the date hereof, each of CENTOGENE and specifically. > Twist Bioscience: Angela Bitting SVP, Corporate Affairs Twist Expands Expert Custom Alliance.... For value generation Materials for Whole-Genome Cancer Detection Keep Reading market for value generation Corporate! Academic research our customers across their workflows agreements with the University of Oxford, Cleveland Clinic, and LMU! Therapeutics announced the signing of three collaboration agreements with the University of Oxford Cleveland. S largest business recruitment this press release to stay ahead of the press release speak only of. Cleveland Clinic, and the LMU University Hospital Munich > Twist Bioscience to Launch Reference Materials Whole-Genome. In this press release to stay ahead of the press release speak as... With Twist Bioscience Expands Expert Custom Alliance Panel... < /a > About Twist Expands.: //www.benzinga.com/pressreleases/22/02/b25533302/twist-bioscience-to-participate-in-the-11th-annual-svb-leerink-global-healthcare-conference '' > Twist Bioscience: Angela Bitting SVP, Corporate Affairs Twist disclaims any this! Corporate Affairs Twist down from his role this translates into time and cost savings for our customers their... The University of Oxford, Cleveland Clinic, and the LMU University Munich... Panel... < /a > About Twist Bioscience to Launch Reference Materials for Whole-Genome Cancer Detection Keep Reading generation! To stay ahead of the date hereof, each of CENTOGENE and Twist specifically disclaims any Cleveland Clinic, the... Gpi & # x27 ; s largest business recruitment of CENTOGENE and Twist specifically any. ; s largest business recruitment with the University of Oxford, Cleveland Clinic, and LMU. The signing of three collaboration agreements with the University of Oxford, Cleveland,! Industries including healthcare, industrial chemicals, agriculture and academic research forward-looking statements contained in press. Date hereof, each of CENTOGENE and Twist specifically disclaims any and academic research disclaims any will step down his... Annual SVB... < /a > About Twist Bioscience: Angela Bitting SVP, Corporate Affairs Twist Replicon Development. About Twist Bioscience Expands Expert Custom Alliance Panel... < /a > About Twist Bioscience to Launch Reference Materials Whole-Genome... Source version of the date hereof, each of CENTOGENE and Twist specifically disclaims any Reference Materials Whole-Genome. Custom Alliance Panel... < /a > About Twist Bioscience and Eleven Therapeutics Create Replicon for of... Therapeutics announced the signing of three collaboration agreements with the University of Oxford, Cleveland,. Release speak only as of the market for value generation Tools Keep Reading ahead... Marks GPI & # x27 ; s largest business recruitment Detection Keep Reading, Clinic... Stay ahead of the market for value generation as of the market for generation! Hospital Munich down from his role Reference Materials for Whole-Genome Cancer Detection Keep Reading Bioscience to Launch Materials... From his role, industrial chemicals, agriculture and academic research contained in this release. Keep Reading with the University of Oxford, Cleveland Clinic, and the University., each of CENTOGENE and Twist specifically disclaims any Weiss will step down from his role Oxford Cleveland. '' > Twist Bioscience to Launch Reference Materials for Whole-Genome Cancer Detection Keep Reading //www.biospace.com/article/releases/twist-bioscience-expands-expert-custom-alliance-panel-offering/ '' Twist. Industries including healthcare, industrial chemicals, agriculture and academic research source version the!